Aglaroxin C and derivatives as HCV entry inhibitors
A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.
Trustees of Boston University SRI International
C A A
C07D A61K A61K
inventional inventional inventional
Neil Tony Tianyi Wenyu John A. Shufeng
Lajkiewicz Wang Wang Porco, Jr. Liu